Provided are a condensed cyclic compound and an organic light-emitting device including the same. The organic light-emitting device may include a first electrode, a second electrode, and an organic layer disposed between the first electrode and the second electrode. The organic layer may include the condensed cyclic compound represented by Formula 1: ##STR00001## In Formula 1, rings A.sub.1, A.sub.2, and A.sub.3 may each be independently a C.sub.5-C.sub.60 carbocyclic group or a C.sub.2-C.sub.30 heterocyclic group, and n1 to n3 may each be independently 0 or 1, provided that the sum of n1, n2, and n3 is 1. In addition, the descriptions of X.sub.1, L.sub.1 to L.sub.9, a1 to a9, Ar.sub.1 to Ar.sub.6, b1 to b6, R.sub.1 to R.sub.3, and c1 to c3 are as defined in the present specification.

Provided are a condensed cyclic compound and an organic light-emitting device including the same. The organic light-emitting device may include a first electrode, a second electrode, and an organic layer disposed between the first electrode and the second electrode. The organic layer may include the condensed cyclic compound represented by Formula 1: ##STR00001## In Formula 1, rings A.sub.1, A.sub.2, and A.sub.3 may each be independently a C.sub.5-C.sub.60 carbocyclic group or a C.sub.2-C.sub.30 heterocyclic group, and n1 to n3 may each be independently 0 or 1, provided that the sum of n1, n2, and n3 is 1. In addition, the descriptions of X.sub.1, L.sub.1 to L.sub.9, a1 to a9, Ar.sub.1 to Ar.sub.6, b1 to b6, R.sub.1 to R.sub.3, and c1 to c3 are as defined in the present specification.

Disclosed are a compound represented by formula (I), a resin including a structural unit derived from the compound, and a resist composition: ##STR00001## wherein R.sup.1 represents an alkyl group which may have a halogen atom, a hydrogen atom or a halogen atom; A.sup.1 represents a single bond or *-A.sup.2-CO—O—; A.sup.2 and A.sup.3 represent an alkanediyl group; W represents a divalent monocyclic saturated alicyclic hydrocarbon group; R.sup.2 and R.sup.3 each represent a hydrogen atom or a hydrocarbon group which may have a fluorine atom, etc., R.sup.4 represents a hydrogen atom, —CH.sub.2— in the group may be replaced by —O—, —S—, etc., R.sup.2 and R.sup.3, or R.sup.2, R.sup.3 and R.sup.4 may be bonded each other to form a ring which may have a fluorine atom or an alkyl group.

Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc. ##STR00001##

Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc. ##STR00001##

Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.

##STR00001##

Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.

##STR00001##

Described herein are methods for synthesizing heterocyclic, 8-membered ring structures. The methods may allow for preparation of highly substituted 8-membered rings. Also disclosed are heterocyclic, 8-membered ring compounds and pharmaceutical compositions comprising the compounds.

Described herein are methods for synthesizing heterocyclic, 8-membered ring structures. The methods may allow for preparation of highly substituted 8-membered rings. Also disclosed are heterocyclic, 8-membered ring compounds and pharmaceutical compositions comprising the compounds.

A photoresist composition containing (A) a polymer having a structural unit (I) that includes an acid-labile group, and (I) a compound represented by the following formula (1). In the following formula (1), R.sup.1, R.sup.2, R.sup.3 and R represent a hydrogen atom or a monovalent organic group having 1 to 20 carbon atoms. X represents a single bond, an oxygen atom or —NR.sup.a—. R.sup.a represents a hydrogen atom, a hydroxy group or a monovalent organic group having 1 to 20 carbon atoms, and optionally taken together represents a ring structure by binding with R each other. A.sup.− represents —SO.sub.3.sup.− or —CO.sub.2.sup.−. M.sup.+ represents a monovalent onium cation. ##STR00001##